SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- Busch: The Debt-Interest Rate Paradox

MORE HEADLINES

» Markets | Economy | Companies

- GM's Agreement to Sell Saab To Swedish Firm Falls Apart

PHARMA'S MARKET VIDEO

» More

Novartis Opens 1st US Plant for Flu Vaccine

4 hrs ago

Novartis is opening on Tuesday the country's first plant to produce flu vaccines using cell cultures. These vaccines are faster, better and cheaper to make than egg-based methods, reports CNBC's Mike Huckman.

Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

16 Nov 2009

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

Cholesterol Drug Battle: Merck vs. Abbott Labs

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Barbara Ryan, pharma analyst at Deutsche Bank Securities, shares her reaction.

Cholesterol Drug Battle 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Pharma's Market

Text Size

Dec.19

3:14 PM ET

Friday, 19 Dec 2008

Vertex's $75,000 Question

Posted By:Mike Huckman

Sectors:Insurance | Health Care Equipment and Services | Health Care | Pharmaceuticals

Companies:Genentech, Inc. | Vertex Pharmaceuticals Incorporated | Johnson and Johnson | Schering Plough Corp

Drug pricing pressure under a Democratic administration be darned. $75,000.

That's not a salary figure. That's the price one biotech analyst says Vertex Pharmaceuticals and its partner Johnson & Johnson [JNJ Loading... () ] might be able to charge--possibly even more--for their Hepatitis C drug.

Shares of VRTX [VRTX Loading... () ] appear to be rallying on that call.

In a research note to clients Bernstein's Geoffrey Porges says after doing a detailed pharmacoeconomic (boy, is that a mouthful) analysis he estimates the companies could charge as much as 75-grand per course.

The drug is in late-stage development. VRTX and JNJ are in a race with Schering-Plough [SGP Loading... () ] to bring a new Hep-C drug to market. Currently available drugs don't work on a lot of patients and even if they do work they make some people feel so sick they can't stay on them. So, there's a big unmet medical need and untapped drug market here.

The $75,000 estimate is $35,000 higher than Porges' previously increased calculation. He's basing the bullish pricing forecast on newer scientific evidence about how well the drug appears to work.

But he cushions the number a bit by writing, "Our model suggests that Vertex could still make a cost effectiveness argument in favor of telaprevir (that's the name of the drug) up to or above $75,000 per patient, though we think it is highly unlikely Vertex will price (it) that high."

A Vertex spokesman says, "We simply do not comment on price at this stage in development."

Vertex is often on the list of usual suspects of biotechs that could be bought.

Bernstein makes a market in VRTX. And someone in Porges' family owns VRTX stock.

Last August Porges predicted Roche might pay as much as $130 a share for Genentech [DNA Loading... () ], but that was before the credit crisis hit and the markets tanked.